单克隆抗体用于癌症治疗

Biosimilars [Working Title] Pub Date : 2021-07-20 DOI:10.5772/INTECHOPEN.97915

A. Livinalli, T. Galvão

{"title":"单克隆抗体用于癌症治疗","authors":"A. Livinalli, T. Galvão","doi":"10.5772/INTECHOPEN.97915","DOIUrl":null,"url":null,"abstract":"Therapeutic monoclonal antibodies have emerged in the 1990 decade as an important option for cancer treatment. These molecules have a diverse set of clinically relevant antitumor mechanisms, directly targeting tumor cells. It has been established as “standard of care” for several human cancers. This chapter reviews the use of monoclonal antibodies in oncology and introduces available biosimilars. The requirements for biosimilar antibody development, mechanisms of action and current clinical applications for cancer treatment is also presented.","PeriodicalId":383787,"journal":{"name":"Biosimilars [Working Title]","volume":"150 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Monoclonal Antibodies for Cancer Treatment\",\"authors\":\"A. Livinalli, T. Galvão\",\"doi\":\"10.5772/INTECHOPEN.97915\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Therapeutic monoclonal antibodies have emerged in the 1990 decade as an important option for cancer treatment. These molecules have a diverse set of clinically relevant antitumor mechanisms, directly targeting tumor cells. It has been established as “standard of care” for several human cancers. This chapter reviews the use of monoclonal antibodies in oncology and introduces available biosimilars. The requirements for biosimilar antibody development, mechanisms of action and current clinical applications for cancer treatment is also presented.\",\"PeriodicalId\":383787,\"journal\":{\"name\":\"Biosimilars [Working Title]\",\"volume\":\"150 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biosimilars [Working Title]\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5772/INTECHOPEN.97915\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biosimilars [Working Title]","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/INTECHOPEN.97915","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

治疗性单克隆抗体在20世纪90年代作为癌症治疗的重要选择而出现。这些分子具有多种临床相关的抗肿瘤机制，直接靶向肿瘤细胞。它已被确立为几种人类癌症的“护理标准”。本章回顾了单克隆抗体在肿瘤学中的应用，并介绍了现有的生物仿制药。本文还介绍了生物类似药抗体开发的要求、作用机制和目前在癌症治疗中的临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Monoclonal Antibodies for Cancer Treatment

Therapeutic monoclonal antibodies have emerged in the 1990 decade as an important option for cancer treatment. These molecules have a diverse set of clinically relevant antitumor mechanisms, directly targeting tumor cells. It has been established as “standard of care” for several human cancers. This chapter reviews the use of monoclonal antibodies in oncology and introduces available biosimilars. The requirements for biosimilar antibody development, mechanisms of action and current clinical applications for cancer treatment is also presented.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biosimilars [Working Title]

自引率

0.00%

发文量